Cover Image
市場調查報告書

醫藥品·生物科技產業上組合式設施的市場:2017-2030年

Modular Facilities in Pharmaceutical / Biotechnology Industry, 2017-2030

出版商 ROOTS ANALYSIS 商品編碼 565306
出版日期 內容資訊 英文 250 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品·生物科技產業上組合式設施的市場:2017-2030年 Modular Facilities in Pharmaceutical / Biotechnology Industry, 2017-2030
出版日期: 2017年10月06日 內容資訊: 英文 250 Pages
簡介

本報告提供全球醫藥品·生物科技產業上組合式設施的市場調查,彙整組合式設施概要,優點,相關法律·標準規格,組合式設施製造商·組合式無塵室供應商的市場環境,主要解決方案供應商簡介,主要計劃概要·分佈,成長機會分析,市場成長預測和各種區分的明細等資料。

第1章 序

第2章 摘要整理

第3章 醫藥品·生物科技產業上組合式設施

  • 本章概要
  • 歷史背景
  • 模組化的概念
    • 模組的各種類型
    • 模組建設流程
  • 醫藥品產業上模組建設
    • 優點
    • 組合式無塵室
    • 法律規章·標準規格

第4章 組合式設施製造商的市場環境

  • 本章概要
  • 製造商:市場環境
    • 各地區分佈
    • 各成立年份分析
    • 不同企業規模分佈
    • 各產業分佈
    • 法律規章上的認證·認證
    • 實行中的模組化計劃

第5章 組合式無塵室供應商的市場環境

  • 本章概要
  • 組合式無塵室供應商:市場環境
    • 各地區分佈
    • 各產業分佈
    • 提供各產品類型的分佈
    • 提供各元件類型的分佈
    • 法律規章上的認證·認證
  • 組合式無塵室零組件供應商

第6章 主要解決方案供應商

  • 本章概要
  • GE Healthcare Life Sciences
  • G-CON Manufacturing
  • Pharmadule Morimatsu
  • ModWave and KeyPlants
  • Jacobs Engineering Group
  • NNE
  • IPM Technologies
  • Germfree Laboratories
  • Biologics Modular
  • WH Partnership
    • 企業概要
    • 提供產品
    • 近幾年的發展
    • 未來展望

第7章 聯盟·其他的發展

  • 本章概要
  • 聯盟模式
  • 聯盟清單
    • 聯盟各年度
    • 聯盟各類型
    • 各地區
    • 主要企業:聯盟各件數
  • 其他的發展趨勢

第8章 近幾年趨勢:組合式設施解決方案

  • 本章概要
  • 醫藥品產業的小規模的組合式設施利用的增加
  • 組合式設施和單回利用技術的整合:彈性和經濟優點
  • 連續的處理技術:組合式方法提供附加價值
  • 企業合作的活躍:服務組合擴大

第9章 未來的成長機會

  • 本章概要
  • 個人化醫療的小規模設施:長期性主要成長推進因素
  • 為了加快上市時間並保持競爭力,幾家生物仿製藥廠商預計將引進組合式設施
  • 利基必要條件·罕見疾病的應對:組合式設施製造商提供補充的市場機會
  • 新興地區:長期性有魅力的市場等

第10章 可行性調查

  • 本章概要
  • 組合式設施計劃
  • 組合式設施的優點
  • 案例研究:KUBio平台

第11章 市場機會分析

  • 本章概要
  • 設施建設計劃
    • 各設施件數
    • 各類設施
    • 各地區
    • 各設施目的
    • 各投資額
    • 各設施規模
  • 預測手法
  • 市場預測
    • 各建設元件類型
    • 各設施規模
    • 各地區
    • 各製造產品類型
    • 各類設施
    • 各設施目的

第12章 總論

第13章 採訪記錄

第14章 附錄 1:圖表資料

第15章 附錄 2:企業·組織清單

目錄
Product Code: RA10091

The business strategies and operational processes in the pharmaceutical industry have regularly evolved over time. Over the past few years, there has been an increased pressure on drug manufacturers to optimize drug development costs and speed up the drug development process. Specifically, with the rise of personalized therapies and orphan drugs, manufacturers are now expected to produce significantly low volumes of a wide range of drugs owing to the patient specific nature of such therapies. In addition, with the increasing number of biosimilars in the pipeline, companies are aiming to reduce the time to market in order to ensure faster patient access. In general, the current market scenario demands the existing operational modes to be altered in such a way that the focus shifts to faster processes, lower manufacturing costs and smaller batch sizes.

Modular facilities have demonstrated tremendous potential in several fields; specifically, the shorter time taken to establish such facilities has a significant impact on expediting various operational processes. Over the years, the interest in such facilities has also gradually risen amongst drug manufacturers within the pharmaceutical and biopharmaceutical industries. In fact, various companies have already transitioned from establishing conventional manufacturing facilities (focused on the large-scale production of a single product) to using small, flexible and modular facilities that can handle multiple products, simultaneously. It has been reported that the time required for the construction of modular facilities, starting from design to approval, could be reduced to half the time required for the construction of conventional facilities. This is primarily due to the fact that modular buildings (modules) are typically constructed offsite, transported to the site and then assembled into fully functional entities. As a consequence of the approach used, facility construction, site preparation and regulatory documentation can proceed in parallel. This is very different from the traditional approach where the aforementioned activities have to be performed sequentially.

Synopsis:

The ‘Modular Facilities in the Pharmaceutical / Biotechnology Industry, 2017-2030’ report provides an extensive studyon the current market landscape and future outlook of modular facility manufacturers that cater to the demands of pharmaceutical and biopharmaceutical companies. The study presents an in-depth analysis of a diverse set of companies that provide complete modular facilities and / or modular cleanrooms to drug researchers / developers. In addition to other elements, the report features:

  • A review of the competitive market landscape of modular facility / modular cleanroom manufacturers with information on their geographical location (North America, Europe, Asia Pacific and rest of the world), establishment year, size (small-sized, mid-sized or large-sized) and type of industries served (pharmaceutical, biotechnology or others). It also includes information on regulatory certifications and recent projects undertaken by these companies.
  • Elaborate profiles of established players that offer a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries; each profile includes a brief overview of the company, information on its financial status, comprehensive modular services portfolio, recent collaborations, information on capability / facility expansionsand an informed future outlook.
  • An analysis of the most active regions based on the locations of modular manufacturing solution providers; the report contains schematic representations of world maps that clearly indicate the modular facility / cleanroom manufacturing hubs.
  • A review of emerging trends, including the combination of single use technologies / continuous processing technologies with modular facilities, the shift to using smaller, multi-purpose and multi-product modular facilities.
  • A discussion on key points that should be considered to facilitate the shift from using conventional facilities to modular facilities. We have provided a case study on JHL Biotech's KUBio biomanufacturing facility, which was constructed by GE Healthcare Life Sciences in China.
  • A detailed discussion on the various growth drivers, such as the development of personalized medicines, biosimilars, orphan drugs, and the anticipated increase in adoption of modular solutions in emerging markets and by pharmaceutical / biopharmaceutical CMOs.
  • A detailed analysis of the collaborations and agreements, covering facility construction agreements, service alliances and acquisitions, which have been established amongst various stakeholders in the past few years.

The study features a detailed analysis on the likely evolution of the pharmaceutical / biotechnology modular manufacturing market over the time period 2017 to 2030. We have provided insights on the expected growth of the market in different regions, including North America, Europe, Asia Pacific and rest of the world. In addition, we have segmented the likely evolution of the market on the basis of type of construction component(process equipment, base building, mechanical, electrical, process utilities, process piping and others), size of the facility (small-sized, mid-sized and large-sized), type of product (small molecules, biologics and others), purpose of facility (manufacturing facility, R&D facility and others) and type of facility (new facility and expansions). In order to account for the uncertainties associated with some of the parameters used and to add robustness to our model, we have presented three different forecast scenarios, depicting conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. The opinions and insights presented in the report were also influenced by discussions with senior stakeholders in the industry. The report presents detailed transcripts of discussions held with Maik Jornitz (CEO, G-CON Manufacturing), Pär Almhem (President, ModWave), Sulogna Roy (Business Development Engineer, Zeton) and Vernon Solomon (President, Environmental Systems Corporation).

Example Highlights:

  • 1. During the course of our study, we identified close to 20 companies that offer modular facilities to pharmaceutical / biotechnology industry. Majority of these companies are located in North America and Europe. Examples of players based in these regions include (in alphabetical order) Biologics Modular, G-CON Manufacturing, GE Healthcare Life Sciences, Germfree Laboratories, IPM Technologies, Jacobs Engineering Group, KeyPlants, ModWave, NNE, Pharmadule Morimatsu and WH Partnership.
  • 2. In addition, there are a number of players that specialize in providing modular cleanrooms; during our research, we identified more than 160 such companies. Of these, there are several companies that solely focus on serving the pharmaceutical and biotechnology industries; examples include (in alphabetical order, no specific shortlisting criteria) American Cleanroom Systems, Asgard Cleanroom Solutions, AWS BIO PHARMA Technologies, CID Associates, Clean Air Flow, Clean Room Depot, Environmental Systems Corporation, Modulus Cleanrooms and Shanghai HJ Modular Cleanroom.
  • 3. Several pharmaceutical and biotechnology companies have adopted the modular concept for constructing new facilities or expanding existing infrastructure. Examples of some established companies include (in alphabetical order) AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Pfizer, Merck, Roche, Novartis and Sanofi. Additionally, small to mid-sized companies that have installed modular facilities include (in alphabetical order) 3P Biotherapeutics, JHL Biotech, Just Biotherapeutics, Stragen Pharma and Strike Bio. In fact, in May 2016, JHL Biotech inaugurated a 2,400 square meters new manufacturing facility, based on the modular KUBio™ platform of GE Healthcare Sciences, at its site in Wuhan, China. More recently, in March 2017, Just Biotherapeutics contracted G-CON Manufacturing for the construction of a cGMP biologics facility in the Hangzhou Economic and Technology Development Area (HEDA) in China. The facility is currently under construction and is anticipated to be completed and operational in early 2018.
  • 4. A number of strategic collaborations have been inked in this domain. We came across over 35 collaborations established during the period 2014-H12017. Majority (~80%) of these collaborations are facility construction agreements. Prominent pharmaceutical / biotechnology modular facility or cleanroom providers that have entered into multiple partnerships include G-CON Manufacturing, GE Healthcare Life Sciences, AES Technology, M+W Group, and Pharmadule Morimatsu.
  • 5. Companies manufacturing niche and emerging therapeutic classes, such as personalized therapies, along with the rising number of biosimilars, hold significant promise for modular facility manufacturers. The adoption of such facilities is also likely to increase in emerging regions, some of which have struggled to meet GMP standards. In addition, CMOs, adopting modular facilities to reduce initial capital investment and handle multiple products, are expected to create incremental business opportunities for modular facility manufacturers.
  • 6. The pharmaceutical / biotechnology modular facilities market is anticipated to grow at an annualized rate of 8.9% during the period 2017 - 2030. Modular facilities for biologics manufacturing are expected to dominate (with more than 80% share) the market. Further, 85% of the overall market share is accounted for by facilities being used for manufacturing purposes. This is followed by facilities for R&D applications (12% of the overall market). In terms of type of facility, the opportunity is likely to be driven by construction of new facilities (65%) followed by modular expansions projects that will likely account for the remaining 35% of the market's share.

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2030, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the current state of the market and its likely evolution in the mid-long term.

Chapter 3 provides a general overview of the modular design concept with information on its historical evolution, types of modules and the modular construction process. It also provides details related to the construction of modular facilities for use in the pharmaceutical / biotechnology industry along with the advantages of these facilities, and information on modular cleanrooms, including their classification and prevalent cleanroom standards.

Chapter 4 includes a comprehensive overview of the landscape of companies that offer pharmaceutical / biotechnology modular facilities. It features an analysis of these service providers on the basis of their geographical location, establishment year, company size and the type of industry served. Additionally, it contains information on regulatory certifications and examples of recent projects undertaken by these companies.

Chapter 5 features a comprehensive overview of the landscape of companies that specialize in offering modular cleanrooms. It features an analysis of the modular cleanroom providers on the basis of their geographical location, type of industry served and the type of modular cleanrooms offered. The chapter also provides information on the components of modular cleanrooms provided by different companies and regulatory certifications of these firms.

Chapter 6 contains detailed profiles of some of the key players that are actively providing modular facilities to pharmaceutical and biotechnology companies. Each company profile includes a brief overview of the company, financial information (if available), details on service offerings, recent developments and an informed future outlook.

Chapter 7 features an elaborate discussion and analysis of the collaborations and partnerships that have been inked amongst players in this market over the last five years (2012 - August 2017). We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this domain. It also lists other recent developments, such as facility / capability expansions and certifications, which have taken place in this domain.

Chapter 8 provides insights on the recent trends in the pharmaceutical / biotechnology industry that are expected to influence the adoption of modular facilities. Some of these trends include the integration of single use / continuous processing technologies with modular facilities, emergence of smaller, multi-purpose, multi-product modular facilities, and collaborations that have been established to provide integrated and flexible modular solutions.

Chapter 9 features a detailed discussion on potential areas, such as rise of personalized medicines, biosimilars and orphan drugs, and increasing adoption of modular solutions in emerging regions and CMOs, which are likely to act as growth drivers in the pharmaceutical / biotechnology modular facilities market, during the coming years.

Chapter 10 presents details on some modular facilities built by various pharmaceutical / biotechnology companies across different geographies. It also includes a discussion on why modular facilities may be preferred over traditional facilities in the long term. Additionally, the chapter includes a case study on JHL Biotech's recent installation of GE Healthcare Life Sciences' KUBio modular biomanufacturing facility, at the former company's site in Wuhan, China.

Chapter 11 presents a comprehensivemarket forecast analysis, highlighting the future potential of the pharmaceutical / biotechnology modular facilities market till the year 2030. We have segregated the opportunity on the basis of type of construction component, size of the facility, type of product, purpose of facility and type of facility. Our estimates are backed by robust analysis of data procured from both secondary and primary sources.

Chapter 12 summarizes the overall report. It presents a list of key takeaways and offers our independent opinion on the current scenario and evolutionary trends that are likely to determine the future of this market in the mid-long term.

Chapter 13 is a collection of transcripts of discussions that were held with key stakeholders in this market.We have presented the details of interviews held with Maik Jornitz (CEO, G-CON Manufacturing), Pär Almhem (President, ModWave), Sulogna Roy (Business Development Engineer, Zeton) and Vernon Solomon (President, Environmental Systems Corporation).

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

Table of Contents

1. Preface

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. Executive Summary

3. Modular Facilities in Pharmaceutical / Biotechnology Industry

  • 3.1. Chapter Overview
  • 3.2. Historical Background
  • 3.3. The Concept of Modularization
    • 3.3.1. Types of Modules
    • 3.3.2. Modular Construction Process
  • 3.4. Modular Construction in the Pharmaceutical Industry
    • 3.4.1. Advantages of Modular Construction in the Pharmaceutical Industry
    • 3.4.2. Pharmaceutical Modular Cleanrooms
      • 3.4.2.1. Cleanroom Classifications and Standards
      • 3.4.2.2. Advantages of Modular Cleanrooms
    • 3.4.3. Regulations and Standards Concerning Modular Cleanroom Construction

4. Market Landscape of Modular Facility Manufacturers in Pharmaceutical / Biotechnology Industry

  • 4.1. Chapter Overview
  • 4.2. Modular Facility Manufacturers: Overall Market Landscape
    • 4.2.1 Modular Facility Manufacturers: Distribution by Geography
    • 4.2.2. Modular Facility Manufacturers: Analysis by Year of Establishment
    • 4.2.3. Modular Facility Manufacturers: Distribution by Company Size
    • 4.2.4. Modular Facility Manufacturers: Distribution by Type of Industry Served
    • 4.2.5. Modular Facility Manufacturers: Regulatory Approvals and Certifications
    • 4.2.6. Modular Facility Manufacturers: Modular Projects Executed / Undertaken

5. Market Landscape of Modular Cleanroom Providers in Pharmaceutical / Biotechnology Industry

  • 5.1. Chapter Overview
  • 5.2. Modular Cleanroom Providers: Overall Market Landscape
    • 5.2.1. Modular Cleanroom Providers: Distribution by Geography
    • 5.2.2. Modular Cleanroom Providers: Distribution by Type of Industry Served
    • 5.2.3. Modular Cleanroom Providers: Distribution by Type of Modular Cleanrooms Offered
    • 5.2.4. Modular Cleanroom Providers: Type of Cleanroom Components Offered
    • 5.2.5. Modular Cleanroom Providers: Regulatory Approvals and Certifications
  • 5.3. Modular Cleanroom Component Providers

6. Pharmaceutical / Biotechnology Modular Facilities: Key Solution Providers

  • 6.1. Chapter Overview
  • 6.2. GE Healthcare Life Sciences
    • 6.2.1. Company Overview
    • 6.2.2. Financial Information
    • 6.2.3. Modular Facility Offerings
    • 6.2.4. Recent Developments
    • 6.2.5. Future Outlook
  • 6.3. G-CON Manufacturing
    • 6.3.1. Company Overview
    • 6.3.2. Financial Information
    • 6.3.3. Modular Facility Offerings
    • 6.3.4. Recent Developments
    • 6.3.5. Future Outlook
  • 6.4. Pharmadule Morimatsu
    • 6.4.1. Company Overview
    • 6.4.2. Modular Facility Offerings
    • 6.4.3. Recent Developments
    • 6.4.4. Future Outlook
  • 6.5. ModWave and KeyPlants
    • 6.5.1. Company Overview
    • 6.5.2. Modular Facility Offerings
    • 6.5.3. Recent Developments
    • 6.5.4. Future Outlook
  • 6.6. Jacobs Engineering Group
    • 6.6.1. Company Overview
    • 6.6.2. Financial Information
    • 6.6.3. Modular Facility Offerings
    • 6.6.4. Recent Developments
    • 6.6.5. Future Outlook
  • 6.7. NNE
    • 6.7.1. Company Overview
    • 6.7.2. Financial Information
    • 6.7.3. Modular Facility Offerings
    • 6.7.4. Recent Developments
    • 6.7.5. Future Outlook
  • 6.8. IPM Technologies
    • 6.8.1. Company Overview
    • 6.8.2. Modular Facility Offerings
    • 6.8.3. Recent Developments
    • 6.8.4. Future Outlook
  • 6.9. Germfree Laboratories
    • 6.9.1. Company Overview
    • 6.9.2. Modular Facility Offerings
    • 6.9.3. Future Outlook
  • 6.10. Biologics Modular
    • 6.10.1. Company Overview
    • 6.10.2. Modular Facility Offerings
    • 6.10.3. Recent Developments
    • 6.10.4. Future Outlook
  • 6.11. WH Partnership
    • 6.11.1. Company Overview
    • 6.11.2. Modular Facility Offerings
    • 6.11.3. Recent Developments
    • 6.11.4. Future Outlook

7. Partnerships and Other Recent Developments

  • 7.1. Chapter Overview
  • 7.2. Partnership Models
  • 7.3. Modular Facilities: List of Partnerships
    • 7.3.1. Modular Facilities: Distribution of Partnerships by Year
    • 7.3.2. Modular Facilities: Distribution of Partnerships by Type
    • 7.3.3. Modular Facilities: Distribution of Partnerships by Geography
    • 7.3.4. Modular Facilities: Leading Players by Number of Partnerships
  • 7.4. Other Recent Developments

8. Recent Trends in Modular Facility Solutions

  • 8.1. Chapter Overview
  • 8.2. The Pharmaceutical Industry is Rapidly Adopting the Use of Smaller, Modular Facilities
  • 8.3. The Integration of Single Use Technologies with Modular Facilities Offers Flexibility as well as Economic Benefits
  • 8.4. Continuous Processing Technologies Offer Added Advantages to the Modular Approach
  • 8.5. The Market is Abuzz with Partnership Activity as Service Providers are Entering into Strategic Alliances in Order to Expand their Service Portfolios

9. Future Growth Opportunities

  • 9.1. Chapter Overview
  • 9.2. Small Scale Facilities for Personalized Therapies are Likely to Emerge as a Key Growth Driver in the Long Term
  • 9.3. In Order to Accelerate Time to Market and Stay Competitive, Several Biosimilar Manufacturers are Expected to Install Modular Facilities
  • 9.4. Addressing the Niche Requirements, Orphan Indications Offer Additional Opportunities for Modular Facility Manufacturers
  • 9.5. Emerging Regions are Likely to be Attractive Markets for Players in the Long Term
  • 9.6. Expansions of Existing Facilities Using Modular Solutions are Projected to Increase Significantly
  • 9.7. Several Contract Manufacturing Organizations are Gradually Shifting Towards Using Modular Solutions

10. Feasibility Study for Modular Facilities in Pharmaceutical / Biotechnology Industry

  • 10.1. Chapter Overview
  • 10.2. Modular Facility Projects Undertaken in the Pharmaceutical / Biotechnology Industry
  • 10.3. Key Advantages of Modular Facilities
    • 10.3.1. Rapid Construction Timelines of such Facilities Result in a Low-risk Investment
    • 10.3.2. Despite the High Initial Investment, Modular Facilities Guarantee High Returns
  • 10.4. Case Study: Modular Facility Based on KUBio Platform
    • 10.4.1. GE Healthcare's KUBio Platform: Overview
    • 10.4.2. JHL Biotech's KUBio Modular Project in China: Overview and Construction Details

11. Opportunity Analysis for the Global Pharmaceutical / Biotechnology Modular Solutions Market

  • 11.1. Chapter Overview
  • 11.2. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Historical Data, 2014-August 2017
    • 11.2.1. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Number of Facilities Per Year, 2014-August 2017
    • 11.2.2. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Type of Facility, 2014-August 2017
    • 11.2.3. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Geography, 2014-August 2017
    • 11.2.4. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Purpose of Facility, 2014-August 2017
    • 11.2.5. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Investment, 2014-August 2017
    • 11.2.6. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Size of the Facility, 2014-August 2017
  • 11.3. Forecast Methodology
  • 11.4. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030
    • 11.4.1. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component
    • 11.4.2. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility
    • 11.4.3. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography
    • 11.4.4. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured
    • 11.4.5. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility
    • 11.4.6. Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility

12. Conclusion

  • 12.1. The Pharmaceutical / Biotechnology Industry is Witnessing an Increasing Need for Flexible, Modular Facilities
  • 12.2. The Landscape of Companies Offering a Wide Range of Modular Solutions Has Evolved Considerably Over the Last Decade
  • 12.3. Several Modular Cleanroom Providers are also Playing a Pivotal Role in the Market's Evolution
  • 12.4. Owing to the Benefits Offered by Modular Facilities, Their Adoption has Gradually Risen
  • 12.5. The Growing Interest in Modular Facilities has Recently Led to the Establishment of Several Key Collaborations
  • 12.6. The Integration of Emerging Technologies with Modular Solutions has Redefined the Applicability and Preferences for Modular Facilities
  • 12.7. Overall, the Market is Anticipated to Witness Significant Growth in the Coming Decade
  • 12.8. Concluding Remarks

13. Interview Transcripts

  • 13.1. Chapter Overview
  • 13.2. Maik Jornitz, CEO, G-CON Manufacturing
  • 13.3. Pär Almhem, President, ModWave
  • 13.4. Sulogna Roy, Business Development Engineer, Zeton
  • 13.5. Vernon Solomon, President, Environmental Systems Corporation

14. Appendix 1: Tabulated Data

15. Appendix 2: List of Companies and Organizations

List of Figures:

  • Figure 3.1: Modular Construction: Applications
  • Figure 3.2: Modular Construction: Processes Involved
  • Figure 3.3: Modular and Conventional Buildings: Construction Timelines
  • Figure 3.4: Modular Construction: Advantages
  • Figure 4.1: Modular Facility Manufacturers: Distribution by Geography
  • Figure 4.2: Modular Facility Manufacturers: Cumulative Number of Companies by Year of Establishment
  • Figure 4.3: Modular Facility Manufacturers: Distribution by Company Size
  • Figure 4.4: Modular Facility Manufacturers: Distribution by Type of Industry Served
  • Figure 5.1: Modular Cleanroom Providers: Distribution by Geography
  • Figure 5.2: Modular Cleanroom Providers: Distribution by Type of Industry Served
  • Figure 5.3: Modular Cleanroom Providers: Distribution by Type of Cleanrooms Provided
  • Figure 6.1: GE Healthcare Life Sciences: Key Operations
  • Figure 6.2: GE Healthcare: Revenues, 2012-2016 (USD Billion)
  • Figure 6.3: GE Healthcare: Revenues by Business Divisions, 2016 (USD Billion)
  • Figure 6.4: G-CON Manufacturing: Types of PODs Offered
  • Figure 6.5: G-CON Manufacturing: Features of the Standard PODs
  • Figure 6.6: G-CON Manufacturing: Applications of PODs
  • Figure 6.7: Pharmadule Morimatsu: Modular Facility Fabrication Process
  • Figure 6.8: KeyPlants: Advantages of Modular Facility
  • Figure 6.9: Jacobs Engineering Group: Revenues, 2012-Q3 2017 (USD Billion)
  • Figure 6.10: Jacobs Engineering Group: Revenues by Services Offered, 2016 (USD Billion)
  • Figure 6.11: Jacobs Engineering Group: Revenues by Business Divisions, 2016 (USD Billion)
  • Figure 6.12: NNE: Services Portfolio
  • Figure 6.13: NNE: Annual Revenues, 2012-2016 (DKK Million)
  • Figure 6.14: NNE: Advantages of Bio on Demand Facility
  • Figure 6.15: IPM Technologies: Applications of Modular Facilities
  • Figure 6.16: Germfree Laboratories: Types and Applications of Modular Facilities Offered
  • Figure 6.17: Germfree Laboratories: Types of BioPharma Lab Modules
  • Figure 7.1: Modular Facilities: Cumulative Number of Partnerships by Year (2012-2017)
  • Figure 7.2: Modular Facilities: Distribution by Type of Partnerships
  • Figure 7.3: Modular Facilities: Distribution of Partnerships by Geography
  • Figure 7.4: Modular Facilities: Leading Players by Number of Partnerships
  • Figure 9.1: Modular Facilities Market: Future Growth Opportunities
  • Figure 10.1: Modular Facilities: Distribution by Company and Location
  • Figure 10.2: Modular Facilities: Example Manufacturers Along with their Clients
  • Figure 10.3: Traditional and Modular Facilities: Analysis of Risk and Probability of Success Across Different Phases of Product Development
  • Figure 10.4: Conventional and Modular Facilities: Comparison of Construction Timelines
  • Figure 10.5: JHL Biotech's KUBio Manufacturing Facility: Construction Process
  • Figure 10.6: KUBio Facility: Construction Timeline
  • Figure 11.1: Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Number of Facilities Per Year, 2014-August 2017
  • Figure 11.2: Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Type of Facility, 2014-August 2017
  • Figure 11.3: Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Geography, 2014-August 2017
  • Figure 11.4: Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Type of Facility, 2014-August 2017
  • Figure 11.5: Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Investment (USD Million), 2014-August 2017
  • Figure 11.6: Facility Construction Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Size of the Facility (sq ft), 2014- August 2017
  • Figure 11.7: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Base Scenario (USD Billion)
  • Figure 11.8: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component, Base Scenario (USD Billion)
  • Figure 11.9: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility, Base Scenario (USD Billion)
  • Figure 11.10: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017, 2025 and 2030: Distribution by Geography (%)
  • Figure 11.11: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography, Base Scenario (USD Billion)
  • Figure 11.12: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured, Base Scenario (USD Billion)
  • Figure 11.13: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility, Base Scenario (USD Billion)
  • Figure 11.14: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility, Base Scenario (USD Billion)
  • Figure 12.1: Global Pharmaceutical / Biotechnology Modular Facilities Market: 2017, 2025 and 2030 (USD Billion)

List of Tables:

  • Table 3.1: Cleanrooms Classification Standards
  • Table 3.2: ISO and FED STD 209E: Cleanroom Classification
  • Table 4.1: Modular Facility Manufacturers
  • Table 4.2: Modular Facility Manufacturers: Distribution by Type of Industry Served
  • Table 4.3: Modular Facility Manufacturers: Regulatory Approvals and Certifications
  • Table 4.4: Modular Facility Manufacturers: Modular Projects Executed / Undertaken
  • Table 5.1: Modular Cleanroom Providers
  • Table 5.2: Modular Cleanroom Providers: Distribution by Type of Industry Served
  • Table 5.3: Modular Cleanroom Providers: Distribution by Type of Modular Cleanrooms Offered
  • Table 5.4: Modular Cleanroom Providers: Distribution by Type of Cleanroom Components Offered
  • Table 5.5: Modular Cleanroom Providers: Regulatory Approvals and Certifications
  • Table 5.6: Modular Cleanroom Component Providers
  • Table 6.1: Modular Manufacturing Facility Providers: List of Companies Profiled
  • Table 6.2: GE Healthcare Life Sciences: KUBio Facility Configurations
  • Table 6.3: G-CON Manufacturing: Dimensions of Standard PODs
  • Table 6.4: Pharmadule Morimatsu: Modular Projects Undertaken
  • Table 6.5: KeyPlants: Modular Projects Undertaken
  • Table 6.6: Jacobs Engineering Group: Pharma Modular Projects Undertaken
  • Table 6.7: NNE: Key Details of API Drug Substance Facility
  • Table 6.8: NNE: Key Details of Final Drug Product Facility
  • Table 6.9: IPM Technologies: Production Capacities of Modular Facilities
  • Table 6.10: Germfree Laboratories: Advantages of BioPharma Modules
  • Table 6.11: Germfree Laboratories: Advantages of BioPharma Lab Modules
  • Table 6.12: Biologics Modular: Features of Modular Cleanrooms
  • Table 6.13: Biologics Modular: Features of Modular Analytical Laboratories and Biorepositories
  • Table 7.1: Modular Facility Manufacturers: Partnerships
  • Table 7.2: Modular Facilities: List of Expansions and Certifications
  • Table 10.1: Modular Facilities: Distribution by Company and Location
  • Table 10.2: PODs, Modular and Conventional Facilities: Comparison of Construction Investment and Financial Returns
  • Table 11.1: Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Historical Data, 2014-August 2017
  • Table 14.1: Modular Facility Manufacturers: Cumulative Number of Companies by Establishment Year
  • Table 14.2: Modular Facility Manufacturers: Distribution by Company Size
  • Table 14.3: Modular Facility Manufacturers: Distribution by Type of Industry Served
  • Table 14.4: Modular Cleanroom Providers: Distribution by Type of Industry Served
  • Table 14.5: Modular Cleanroom Providers: Distribution by Type of Cleanrooms Offered
  • Table 14.6: GE Healthcare: Revenues, 2012-2016 (USD Billion)
  • Table 14.7: GE Healthcare: Revenues by Business Divisions, 2016 (USD Billion)
  • Table 14.8: Jacobs Engineering Group: Revenues, 2012-Q3 2017 (USD Billion)
  • Table 14.9: Jacobs Engineering Group: Revenues by Services Offered, 2016 (USD Billion)
  • Table 14.10: Jacobs Engineering Group: Revenues by Business Divisions, 2016 (USD Billion)
  • Table 14.11: NNE: Annual Revenues, 2012-2016 (DKK Million)
  • Table 14.12: Modular Facilities: Cumulative Number of Partnerships by Year (2012-2017)
  • Table 14.13: Modular Facilities: Distribution by Type of Partnerships
  • Table 14.14: Modular Facilities: Distribution of Partnerships by Geography
  • Table 14.15: Modular Facilities: Leading Players by Number of Partnerships
  • Table 14.16: Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Number of Facilities Per Year, 2014-August 2017
  • Table 14.17: Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Type of Facility, 2014-August 2017
  • Table 14.18: Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Geography, 2014-August 2017
  • Table 14.19: Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Purpose of Facility, 2014-August 2017
  • Table 14.20: Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Investment, 2014-August 2017 (USD Million)
  • Table 14.21: Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Distribution by Size of the Facility, 2014-August 2017
  • Table 14.22: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Conservative Scenario (USD Billion)
  • Table 14.23: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Base Scenario (USD Billion)
  • Table 14.24: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Optimistic Scenario (USD Billion)
  • Table 14.25: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component, Conservative Scenario (USD Billion)
  • Table 14.26: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component, Base Scenario (USD Billion)
  • Table 14.27: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Construction Component, Optimistic Scenario (USD Billion)
  • Table 14.28: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility, Conservative Scenario (USD Billion)
  • Table 14.29: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility, Base Scenario (USD Billion)
  • Table 14.30: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Size of the Facility, Optimistic Scenario (USD Billion)
  • Table 14.31: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography (%)
  • Table 14.32: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography, Conservative Scenario (USD Billion)
  • Table 14.33: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography, Base Scenario (USD Billion)
  • Table 14.34: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Geography, Optimistic Scenario (USD Billion)
  • Table 14.35: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured, Conservative Scenario (USD Billion)
  • Table 14.36: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured, Base Scenario (USD Billion)
  • Table 14.37: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Product Manufactured, Optimistic Scenario (USD Billion)
  • Table 14.38: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility, Conservative Scenario (USD Billion)
  • Table 14.39: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility, Base Scenario (USD Billion)
  • Table 14.40: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Type of Facility, Optimistic Scenario (USD Billion)
  • Table 14.41: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility, Conservative Scenario (USD Billion)
  • Table 14.42: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility, Base Scenario (USD Billion)
  • Table 14.43: Global Pharmaceutical / Biotechnology Modular Facilities Market, 2017-2030: Distribution by Purpose of Facility, Optimistic Scenario (USD Billion)
  • Table 14.44: Global Pharmaceutical / Biotechnology Modular Facilities Market: 2017, 2025 and 2030 (USD Billion)

Company Listed:

The following companies and organizations have been mentioned in the report.

  • 1.209 Technologies
  • 2.A&M Project Services
  • 3.AASTHA CLEANROOM SYSTEMS
  • 4.ABN Cleanroom Technology
  • 5.Abtech
  • 6.ACH Engineering
  • 7.Acumen Technology
  • 8.A.D. Cleanrooms Engineering
  • 9.ADDvise
  • 10.AES Clean Technology
  • 11.Air Innovations
  • 12.Airgas
  • 13.Airology
  • 14.Air Micron Cleantech
  • 15.Aircare Projects
  • 16.Airtech Systems
  • 17.AJNI Industries
  • 18.Ajinomoto North America
  • 19.AKERTEC
  • 20.Albian Group
  • 21.Alembic Pharmaceuticals
  • 22.Allied Cleanrooms
  • 23.Alnylam Pharmaceuticals
  • 24.AME For Industry
  • 25.AM Cleanroom Build and Performance
  • 26.American Cleanroom Systems
  • 27.Angstrom Technology
  • 28.Aqvida
  • 29.Arthrex
  • 30.Asgard Cleanroom Solutions
  • 31.AstraZeneca
  • 32.AWS BIO PHARMA TECHNOLOGIES
  • 33.Axenic Systems
  • 34.Bangalore Air Tech Solution
  • 35.Bassaire
  • 36.Baxter
  • 37.bc-technology
  • 38.Belcher Equipment
  • 39.Bode Equipment
  • 40.BioCon Solutions
  • 41.Biogen
  • 42.Bigneat
  • 43.Bioinspection
  • 44.Biologics Modular
  • 45.Biosoft
  • 46.Bouygues Energies & Services
  • 47.Bristol-Myers Squibb
  • 48.Broad Sustainable Building
  • 49.Butler Manufacturing
  • 50.Cambridge Cleanroom
  • 51.CID Associates
  • 52.Cipharm
  • 53.Clean Air Flow
  • 54.Clean Air Products
  • 55.Clean Air Systems
  • 56.Clean Air Technology
  • 57.Clean Modules
  • 58.Cleanrooms Australia
  • 59.Cleanroom Equipment
  • 60.Cleanroom Solutions
  • 61.ClearSphere
  • 62.Clean Room Depot
  • 63.Clean Rooms International
  • 64.Clean Rooms Plus
  • 65.Clean Rooms West
  • 66.Clean Zone Technology
  • 67.CleanAir Solutions
  • 68.Cleanroom Ceiling Systems (a division of Varni Enterprises)
  • 69.Cleanroom Results
  • 70.Cleanroom Synergy
  • 71.Cleanrooms By United
  • 72.CleanZones
  • 73.CLEEMS
  • 74.Clestra Cleanroom
  • 75.Cook Imaging
  • 76.Connect 2 Cleanrooms
  • 77.CONSAB International
  • 78.CRB Consulting Engineers
  • 79.Design Filtration Microzone
  • 80.Dortek Hygienic Doors
  • 81.Dr. Reddy's Laboratories
  • 82.Dynamic Manufacturing Solutions
  • 83.Ebtech Industrial Modular Building Solutions
  • 84.Eli Lilly
  • 85.E- Pack Polymers
  • 86.Enbloc
  • 87.Environmental Systems Corporation
  • 88.Envair Electrodyne
  • 89.Fabtech Technologies International
  • 90.Filtration Technology
  • 91.Firmament Technology
  • 92.Florida Cleanroom Systems
  • 93.Foothills Systems
  • 94.Flowstar
  • 95.Fluor
  • 96.Galderma
  • 97.Guardtech Cleanrooms
  • 98.G-CON Manufacturing
  • 99.GE Healthcare Life Sciences
  • 100.Genentech
  • 101.Gerbig Engineering Company
  • 102.Germfree Laboratories
  • 103.Gilcrest Manufacturing
  • 104.GlaxoSmithKline
  • 105.Glowmax Engineers
  • 106.GMP Technical Solutions
  • 107.GMPMax Pharma
  • 108.Green Carrier Consultancy and Tech Solutions
  • 109.Halco Products
  • 110.Hectra Enviro Systems
  • 111.Hemair Systems
  • 112.HEMCO Corporation
  • 113.HEPAire Products Corporation
  • 114.Hermetel Oy
  • 115.Hodess Construction
  • 116.Huntair
  • 117.Iberconcept
  • 118.Innclose
  • 119.Innotech Products
  • 120.Innovative Cleanroom Technologies
  • 121.InPlant Offices
  • 122.Instaspace
  • 123.Integrated Clean Room Technologies
  • 124.IPM Technologies
  • 125.Isoflex Systems
  • 126.IsoTech Design
  • 127.Jacobs Engineering Group
  • 128.JHL Biotech
  • 129.JMC Project Services
  • 130.Just Biotherapeutics
  • 131.KABTech Corporation
  • 132.KeyPlants
  • 133.Kingspan
  • 134.Kleantech Engineering Systems
  • 135.KTEC Cleanroom Systems
  • 136.Labard Instruchem
  • 137.Labover
  • 138.Labworks International
  • 139.Lasco Services
  • 140.Lennox Clean Room Technologies
  • 141.Liberty Industries
  • 142.LifeTek Solutions
  • 143.LM Air Technology
  • 144.Longden Company
  • 145.Lonza
  • 146.Mabion
  • 147.Mach-Aire
  • 148.MAK Clean Air Systems
  • 149.Mallinckrodt Pharmaceuticals
  • 150.Mars Sterile Solutions
  • 151.McDonald's
  • 152.MDI
  • 153.MECART
  • 154.Medipharma
  • 155.Merck
  • 156.Merit Holdings
  • 157.Microbinc
  • 158.Microzone Corporation
  • 159.MK Precision
  • 160.Moduclean
  • 161.Mobius Controlled Environments
  • 162.Modubuild
  • 163.Modulus Cleanrooms
  • 164.Modular Cleanrooms
  • 165.ModWave
  • 166.Monmouth Scientific
  • 167.Morimatsu Industry Group
  • 168.M P Prime Structures
  • 169.MRC Systems
  • 170.MTX Contracts
  • 171.M+W Group
  • 172.Nano Clean
  • 173.National Partitions
  • 174.NextCell Pharma
  • 175.NGS Cleanroom Solutions
  • 176.Nicomac
  • 177.NNE
  • 178.Norwood Group
  • 179.Novartis
  • 180.Novo Nordisk
  • 181.Octapharma
  • 182.OCTANORM
  • 183.OSB Prefab Technologies
  • 184.Pacific Environmental Technologies
  • 185.Panel Built
  • 186.Parteco
  • 187.PC Company
  • 188.Pfizer
  • 189.PermaTherm
  • 190.Pharmacia
  • 191.Pharmacon
  • 192.Pharmadule Morimatsu
  • 193.Pharmintech Turnkey Solutions
  • 194.Plascore
  • 195.Poppleton
  • 196.PortaFab
  • 197.Porta-King Building Systems
  • 198.Power And Motion
  • 199.Precision Air Technology
  • 200.Precision Cleanrooms
  • 201.Precision Engineering design
  • 202.ProCleanroom
  • 203.Progenitor Cell Therapy
  • 204.QleanAir Scandinavia
  • 205.Riddhi Metals
  • 206.Rinac India
  • 207.Robert Soper
  • 208.Sartorius Stedim Biotech
  • 209.Sapphire Cleanrooms
  • 210.Sears Roebuck and Company
  • 211.SCHILLING ENGINEERING
  • 212.Schering-Plough
  • 213.Shanghai HJ Modular Cleanroom
  • 214.SRS Shelving + Rack Systems
  • 215.Skylark Engineering Technologies
  • 216.Simplex Isolation Systems
  • 217.SML Clean Room Solutions
  • 218.Solutions and Handling
  • 219.Span Construction and Engineering
  • 220.Srprefabs Modular Cleanroom
  • 221.Starrco
  • 222.Stefatos
  • 223.Sterlitech
  • 224.Stevenage BioScience Catalyst
  • 225.Stodec Products
  • 226.SUNBEL
  • 227.Suntec Teknopak
  • 228.Stragen Pharma
  • 229.Swedish Modules
  • 230.Synergy Thrislington
  • 231.SZ Airkey Environmental Tech & Eng
  • 232.Tabuk Pharmaceuticals
  • 233.TCM (The Cleanroom Market)
  • 234.Technical Air Products
  • 235.Ted Thorsen Material Handling
  • 236.Telstar Life Science Solutions
  • 237.Termovent
  • 238.Terra Universal
  • 239.Teruisi Pharmaceutical
  • 240.Teva Pharmaceutical
  • 241.The Softwall Shop
  • 242.Travis Clean Air
  • 243.Tudela International
  • 244.Turnkey Modular Systems
  • 245.Ultrapure Technology
  • 246.United BioPharma
  • 247.United Partition Systems
  • 248.United Pharmaceuticals
  • 249.University of Tennessee Health Science Center
  • 250.Vanguard Modular Building Systems
  • 251.Vernick & Associates
  • 252.VRP CLEAN ROOM SYSTEMS
  • 253.Weaver Technologies
  • 254.Westbury Cleanrooms
  • 255.Western Environmental Corporation
  • 256.Whitenair Technologies
  • 257.WH Partnership
  • 258.w.w. Cannon
  • 259.XBiotech
  • 260.XCounter
  • 261.Xytel
  • 262.YRS Enterprises
  • 263.Zeton
Back to Top